FDA oncological drugs advisory committee votes in support of Tecentriq in bladder cancer – Genentech/Roche
Genentech/Roche announced the FDA Oncologic Drugs Advisory Committee voted 10 to 1 in favor of maintaining accelerated approval of Tecentriq (atezolizumab) for the treatment of adults with locally… read more.